Zobrazeno 1 - 10
of 309
pro vyhledávání: '"Alan H. Bryce"'
Autor:
City of Hope
Publikováno v:
Business Wire (English). 11/07/2023.
Autor:
Holly M Thomson, Shannon P Fortin Ensign, Victoria S Edmonds, Akanksha Sharma, Richard J Butterfield, Steven E Schild, Jonathan B Ashman, Richard S Zimmerman, Naresh P Patel, Alan H Bryce, Sujay A Vora, Terence T Sio, Alyx B Porter
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 17 (2023)
Background: Radiation necrosis (RN) is a clinically relevant complication of stereotactic radiosurgery (SRS) for intracranial metastasis (ICM) treatments. Radiation necrosis development is variable following SRS. It remains unclear if risk factors fo
Externí odkaz:
https://doaj.org/article/48a5805074b749edbe98ab54b51bf596
Autor:
Aaron S. Mansfield, David S. Hong, Christine L. Hann, Anna F. Farago, Himisha Beltran, Saiama N. Waqar, Andrew E. Hendifar, Lowell B. Anthony, Matthew H. Taylor, Alan H. Bryce, Scott T. Tagawa, Karl Lewis, Jiaxin Niu, Christine H. Chung, James M. Cleary, Michael Rossi, Carrianne Ludwig, Ricardo Valenzuela, Yan Luo, Rahul Aggarwal
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-7 (2021)
Abstract Delta-like protein 3 (DLL3) is highly expressed in solid tumors, including neuroendocrine carcinomas/neuroendocrine tumors (NEC/NET). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting antibody-drug conjugate. Patients with NECs and other
Externí odkaz:
https://doaj.org/article/41cea5032a0d44ac9ceef9a9bed44b7a
Autor:
Daniel D. Karp, D. Ross Camidge, Jeffery R. Infante, Tyler D. Ames, Matthew R. Price, José Jimeno, Alan H. Bryce
Publikováno v:
EClinicalMedicine, Vol 49, Iss , Pp 101430- (2022)
Summary: Background: PT-112, the first pyrophosphate-platinum conjugate, causes immunogenic cell death in experimental models, leading to recruitment of tumour-infiltrating lymphocytes. PT-112 also associates with bone (osteotropism), likely driven b
Externí odkaz:
https://doaj.org/article/ac87d13436ea457596df59d56074eb82
Autor:
Suryadipto Sarkar, Kong Min, Waleed Ikram, Ryan W. Tatton, Irbaz B. Riaz, Alvin C. Silva, Alan H. Bryce, Cassandra Moore, Thai H. Ho, Guru Sonpavde, Haidar M. Abdul-Muhsin, Parminder Singh, Teresa Wu
Publikováno v:
Cancers, Vol 15, Iss 6, p 1673 (2023)
Accurate clinical staging of bladder cancer aids in optimizing the process of clinical decision-making, thereby tailoring the effective treatment and management of patients. While several radiomics approaches have been developed to facilitate the pro
Externí odkaz:
https://doaj.org/article/da6a23fb62a04e07a4317c82410a7ae4
Autor:
Rahul Aggarwal, Joshi J. Alumkal, Russell Z. Szmulewitz, Celestia S. Higano, Alan H. Bryce, Angela Lopez-Gitlitz, Sharon A. McCarthy, Branko Miladinovic, Kelly McQuarrie, Shibu Thomas, Ke Zhang, Eric J. Small
Publikováno v:
Prostate Cancer, Vol 2022 (2022)
Purpose. This randomized phase 2 study sought to assess the treatment effect of a finite duration of apalutamide with and without androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BCR PC). Materials and Methods. Patients
Externí odkaz:
https://doaj.org/article/ca0c2ba8c68e4aca981effd45231b1a2
Autor:
Andrea Loehr, Arif Hussain, Akash Patnaik, Alan H. Bryce, Daniel Castellano, Albert Font, Jeremy Shapiro, Jingsong Zhang, Brieuc Sautois, Nicholas J. Vogelzang, Gurkamal Chatta, Kevin Courtney, Andrea Harzstark, Francesco Ricci, Darrin Despain, Simon Watkins, Charmin King, Minh Nguyen, Andrew D. Simmons, Simon Chowdhury, Wassim Abida
Publikováno v:
European Urology. 83:200-209
Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are approved in the USA for the treatment of patients with BRCA1 or BRCA2 (BRCA) mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC). BRCA reversion mutations are a k
Autor:
Karim Fizazi, Josep M. Piulats, M. Neil Reaume, Peter Ostler, Ray McDermott, Joel R. Gingerich, Elias Pintus, Srikala S. Sridhar, Richard M. Bambury, Urban Emmenegger, Henriette Lindberg, David Morris, Franco Nolè, John Staffurth, Charles Redfern, María I. Sáez, Wassim Abida, Gedske Daugaard, Axel Heidenreich, Laurence Krieger, Brieuc Sautois, Andrea Loehr, Darrin Despain, Catherine A. Heyes, Simon P. Watkins, Simon Chowdhury, Charles J. Ryan, Alan H. Bryce
Publikováno v:
New England Journal of Medicine. 388:719-732
Autor:
Patricia M LoRusso, Aleksandar Sekulic, Jeffrey A Sosman, Winnie S Liang, John Carpten, David W Craig, David B Solit, Alan H Bryce, Jeffrey A Kiefer, Jessica Aldrich, Sara Nasser, Rebecca Halperin, Sara A Byron, Mary Jo Pilat, Scott A Boerner, Diane Durecki, William P D Hendricks, Daniel Enriquez, Tyler Izatt, Jonathan Keats, Christophe Legendre, Svetomir N Markovic, Amy Weise, Fatima Naveed, Jessica Schmidt, Gargi D Basu, Shobana Sekar, Jonathan Adkins, Erica Tassone, Karthigayini Sivaprakasam, Victoria Zismann, Valerie S Calvert, Emanuel F Petricoin, Leslie Anne Fecher, Christopher Lao, J Paul Eder, Nicholas J Vogelzang, Jane Perlmutter, Mark Gorman, Barbara Manica, Lisa Fox, Nicholas Schork, Daniel Zelterman, Michelle DeVeaux, Richard W Joseph, C Lance Cowey, Jeffrey M Trent
Publikováno v:
PLoS ONE, Vol 16, Iss 4, p e0248097 (2021)
Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAFV600 mutations, targeted agents have been ineffective for BRAFV600wild-type (wt) metastatic melanomas. The SU2C Genomics-
Externí odkaz:
https://doaj.org/article/ea286e5ad5d3466fb04534c8639561db
Autor:
Thomas T DeLeon, Daniel R Almquist, Benjamin R Kipp, Blake T Langlais, Aaron Mangold, Jennifer L Winters, Heidi E Kosiorek, Richard W Joseph, Roxana S Dronca, Matthew S Block, Robert R McWilliams, Lisa A Kottschade, Kandelaria M Rumilla, Jesse S Voss, Mahesh Seetharam, Aleksandar Sekulic, Svetomir N Markovic, Alan H Bryce
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0230306 (2020)
BACKGROUND:CDKN2A and TP53 mutations are recurrent events in melanoma, occurring in 13.3% and 15.1% of cases respectively and are associated with poorer outcomes. It is unclear what effect CDKN2A and TP53 mutations have on the clinical outcomes of pa
Externí odkaz:
https://doaj.org/article/3927fd1a2b3d44719753600a2b2972b4